Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion in an all cash transaction. The deal brings Terns’ promising pipeline of oncology assets, particularly its selective CDK7 inhibitor and other targeted therapies, into Merck’s growing cancer portfolio, aiming to accelerate development of next generation treatments for difficult to treat tumors.
Glimpse:
The $6.7 billion acquisition includes Terns’ lead candidate, a highly selective CDK7 inhibitor currently in early clinical development for solid tumors, along with additional preclinical programs in oncology. Merck will gain access to Terns’ innovative small-molecule platform and experienced R&D team. The transaction is expected to close in the second half of 2026, subject to regulatory approvals, and reflects Merck’s continued strategy of bolstering its oncology pipeline through strategic acquisitions of high-potential assets.
Merck & Co., Inc. (known as MSD outside the United States and Canada) has announced a definitive agreement to acquire Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing small molecule therapies for oncology and other serious diseases, in an all cash transaction valued at $6.7 billion. The deal, announced on February 26, 2026, underscores Merck’s aggressive approach to strengthening its oncology pipeline through the addition of innovative targeted agents.
Terns Pharmaceuticals’ lead asset is a highly selective cyclin dependent kinase 7 (CDK7) inhibitor currently in early phase clinical trials for the treatment of advanced solid tumors. CDK7 inhibition is considered a promising approach because it targets a key regulator of transcription and cell cycle progression, potentially addressing resistance mechanisms seen with existing therapies. The acquisition also includes Terns’ broader pipeline of preclinical programs in oncology, which Merck plans to integrate into its internal research and development efforts.
Merck’s Chief Scientific Officer stated that the addition of Terns’ CDK7 program and related assets aligns with the company’s strategy to build a diverse and differentiated oncology portfolio, particularly in areas of high unmet need such as difficult to treat solid tumors. The transaction is expected to enhance Merck’s capabilities in small molecule drug discovery and provide new opportunities for combination therapies with its existing immuno oncology and targeted agents.
The deal is subject to customary closing conditions, including regulatory approvals and approval by Terns’ shareholders. It is anticipated to close in the second half of 2026. Following completion, Terns Pharmaceuticals will become a wholly owned subsidiary of Merck, and its operations will be integrated into Merck’s oncology research and development organization.
This acquisition continues a series of strategic moves by Merck to bolster its pipeline in oncology and other high growth therapeutic areas, reflecting confidence in the long term potential of innovative targeted therapies to address challenging cancers.
“Terns’ innovative CDK7 inhibitor and broader pipeline represent a compelling addition to our oncology portfolio. We look forward to advancing these promising candidates to deliver meaningful benefits to patients with difficult to treat cancers.”
By
HB Team
Related News
